Animas Corporation, a Johnson & Johnson company, is dedicated to making diabetes management easier through product innovation, exceptional customer support and customized education programs. The OneTouch® PingTM glucose management system is the company's sixth generation insulin delivery product since the company was founded in 1996. The OneTouch® PingTM glucose management system, from OneTouch® and Animas®, is an insulin pump and a meter-remote that communicate wirelessly, to help you perform at your best. The pump is packed with unique capabilities that may be accessed directly from the pump or wirelessly using the meter-remote. And the meter-remote, with its full set of functions, is designed to help make your life with diabetes easier and more discreet. Other features include a color screen, access to a 500-item food database from CalorieKing® and the smallest basal rate/increment. Plus the pump is waterproof*! Animas also offers customized education programs and 24/7 pump technical support. Animas is pleased to be a sponsor of the 2010 Regional Conference Series. (*The meter-remote must not be exposed to water.)
Disetronic Medical Systems is a member of The Roche Group, a leader in diabetes care and the manufacturer of ACCU-CHEK® products and services. We are one of the largest manufacturers of insulin pumps in the world and a leading supplier of infusion sets and supplies for almost all brands of insulin pumps. Disetronic has more than 20 years experience in pump therapy research, development, and manufacturing. Successful insulin pumping is a team effort by patients, healthcare providers, and product and service providers like Disetronic. We are dedicated to being an active and committed team member. We maintain excellent customer service providing online and phone ordering services for insulin pump supplies and our Pump Support team is available 24 hours a day, 365 days per year to respond to your questions concerning the operation of your insulin pump and supplies. Disetronic is proud to support CWD's 2010 regional conference series.
The Juvenile Diabetes Research Foundation International is the world's largest charitable funder and advocate of type 1 diabetes research. Founded in 1970 by parents of children with type 1 diabetes, JDRF's mission is to find a cure for diabetes and its complications through the support of research. Over the years, JDRF has provided more than $1 billion in grants for diabetes research at universities and laboratories around the world. In addition to its role in leading research funding, JDRF is accessible to people 24 hours per day, seven days per week--particularly those struggling with the difficult moments after a diagnosis of diabetes. Through its Web site and more than 100 locations worldwide, JDRF has developed a diverse support network for families with a type 1 connection, including a number of personal family-to-family programs and a range of resources. JDRF is proud to support CWD's 2010 Regional Conference Series. For more information, visit the JDRF Web site at www.jdrf.org, or call 800-533-CURE.
OneTouch® is committed to creating a world without limits for people with diabetes. Through our industry-leading OneTouch® products and support, we are able to provide patients and healthcare professionals with a comprehensive system to assist with blood glucose management. At OneTouch®, we provide accurate and reliable products – inside every OneTouch® Ultra® Blue Test Strip is DoubleSure™ technology that automatically checks each blood sample not once, but twice. So you’re not just sure of the test result, you're DoubleSure™. We understand that the more confident you and your child are with your results, the more you can focus on living your life. OneTouch®, an early supporter of Children With Diabetes, is proud to be a sponsor of the 2010 regional conference Series.
Novo Nordisk is dedicated to improving the lives of individuals with diabetes. For nearly 80 years, the company has combined drug discovery with state-of-the-art technology to develop leading edge products for people with diabetes. Novo Nordisk was the first to develop longer-acting NPH insulin, purified insulin, and premixed human insulin. Novo Nordisk also designed the first durable and disposable insulin pen devices and the first dial-a-dose insulin delivery system. Novo Nordisk recently added a rapid-acting human insulin analog, NovoLog® (insulin aspart [rDNA origin] injection) as another treatment option for people with diabetes. Novo Nordisk is proud to be a sponsor of the 2010 CWD Regional Conference Series.
Sanofi-Aventis is pleased to be a sponsor of the 2010 CWD Regional Conference Series.
Houston 2010: Focus on Technology Conference - Faculty and Staff - Registration
Program - Youth program - Sponsors
|Return to the Top of This Page|
Last Updated: Monday January 18, 2010 12:58:00
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.